Najnowsze artykuły:

Bio-Techne outlines temporary cell therapy headwinds and expects low single-digit FY26 growth while margin expands

Q1 2026 Management View Kim Kelderman, CEO, President & Director, reported that organic revenue declined 1% in Q1, attributing the decrease primarily to clinical stage timing from large cell therapy ...

Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and ...

DURHAM, N.C., May 14, 2025--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene ...

url.com.pl

Menu

Reklama

Najnowsze artykuły:

Bio-Techne outlines temporary cell therapy headwinds and expects low single-digit FY26 growth while margin expands

Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and ...